{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:30:45Z","timestamp":1793658645822,"version":"4.5.1"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000032","name":"Institute of Infection and Immunity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00018-019-03156-8","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T10:03:47Z","timestamp":1558778627000},"page":"3583-3600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1683-710X","authenticated-orcid":false,"given":"Ivan","family":"Sadowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad B.","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,25]]},"reference":[{"key":"3156_CR1","first-page":"1","volume-title":"Fact sheet\u2014latest global and regional statistics on the status of the AIDS epidemic","author":"UNAIDS","year":"2018","unstructured":"UNAIDS (2018) Fact sheet\u2014latest global and regional statistics on the status of the AIDS epidemic. UNAIDS, Geneva, pp 1\u20136"},{"key":"3156_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bcp.2017.07.001","volume":"146","author":"C Schwartz","year":"2017","unstructured":"Schwartz C, Bouchat S, Marban C et al (2017) On the way to find a cure: purging latent HIV-1 reservoirs. Biochem Pharmacol 146:10\u201322. https:\/\/doi.org\/10.1016\/j.bcp.2017.07.001","journal-title":"Biochem Pharmacol"},{"key":"3156_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/AID.2017.0310","volume":"34","author":"RC Landis","year":"2018","unstructured":"Landis RC, Abayomi EA, Bain BC et al (2018) Shifting the HIV paradigm from care to cure: proceedings from the caribbean expert summit in Barbados, August 2017. AIDS Res Hum Retrovir 34:561\u2013569. https:\/\/doi.org\/10.1089\/AID.2017.0310","journal-title":"AIDS Res Hum Retrovir"},{"key":"3156_CR4","first-page":"1","volume-title":"90-90-90: An ambitious treatment target to help end the AIDS epidemic","author":"UNAIDS","year":"2014","unstructured":"UNAIDS (2014) 90-90-90: An ambitious treatment target to help end the AIDS epidemic. UNAIDS, Geneva, pp 1\u201340"},{"key":"3156_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fchem.2017.00023","volume":"5","author":"TJ Meyer","year":"2017","unstructured":"Meyer TJ, Rosenkrantz JL, Carbone L, Chavez SL (2017) Endogenous retroviruses: with Us and against Us. Front Chem 5:23. https:\/\/doi.org\/10.3389\/fchem.2017.00023","journal-title":"Front Chem"},{"key":"3156_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/COH.0b013e328361fabd","volume":"8","author":"JR Arribas","year":"2013","unstructured":"Arribas JR, Eron J (2013) Advances in antiretroviral therapy. Curr Opin HIV AIDS 8:341\u2013349. https:\/\/doi.org\/10.1097\/COH.0b013e328361fabd","journal-title":"Curr Opin HIV AIDS"},{"key":"3156_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jiac.2016.10.002","volume":"23","author":"K Yoshimura","year":"2017","unstructured":"Yoshimura K (2017) Current status of HIV\/AIDS in the ART era. J Infect Chemother 23:12\u201316. https:\/\/doi.org\/10.1016\/j.jiac.2016.10.002","journal-title":"J Infect Chemother"},{"key":"3156_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s10461-010-9792-y","volume":"15","author":"KC Duncan","year":"2010","unstructured":"Duncan KC, Reading C, Borwein AM et al (2010) HIV incidence and prevalence among aboriginal peoples in Canada. AIDS Behav 15:214\u2013227. https:\/\/doi.org\/10.1007\/s10461-010-9792-y","journal-title":"AIDS Behav"},{"key":"3156_CR9","first-page":"1","volume-title":"UNAIDS report on the global AIDS epidemic 2013","author":"UNAIDS","year":"2013","unstructured":"UNAIDS (2013) UNAIDS report on the global AIDS epidemic 2013. UNAIDS, Geneva, pp 1\u2013198"},{"key":"3156_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.idc.2017.07.007","volume":"31","author":"P Van Epps","year":"2017","unstructured":"Van Epps P, Kalayjian RC (2017) Human immunodeficiency virus and aging in the era of effective antiretroviral therapy. Infect Dis Clin N Am 31:791\u2013810. https:\/\/doi.org\/10.1016\/j.idc.2017.07.007","journal-title":"Infect Dis Clin N Am"},{"key":"3156_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coviro.2016.02.001","volume":"18","author":"AR Cillo","year":"2016","unstructured":"Cillo AR, Mellors JW (2016) Which therapeutic strategy will achieve a cure for HIV-1? Curr Opin Virol 18:14\u201319. https:\/\/doi.org\/10.1016\/j.coviro.2016.02.001","journal-title":"Curr Opin Virol"},{"key":"3156_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines5010005","author":"DC Macallan","year":"2017","unstructured":"Macallan DC, Borghans JAM, Asquith B (2017) Human T cell memory: a dynamic view. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines5010005","journal-title":"Vaccines (Basel)"},{"key":"3156_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1089\/AID.2018.0118","volume":"34","author":"S Castro-Gonzalez","year":"2018","unstructured":"Castro-Gonzalez S, Colomer-Lluch M, Serra-Moreno R (2018) Barriers for HIV cure: the latent reservoir. AIDS Res Hum Retrovir 34:739\u2013759. https:\/\/doi.org\/10.1089\/AID.2018.0118","journal-title":"AIDS Res Hum Retrovir"},{"key":"3156_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12977-016-0323-4","volume":"13","author":"AJ Kandathil","year":"2016","unstructured":"Kandathil AJ, Sugawara S, Balagopal A (2016) Are T cells the only HIV-1 reservoir? Retrovirology 13:86. https:\/\/doi.org\/10.1186\/s12977-016-0323-4","journal-title":"Retrovirology"},{"key":"3156_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/COH.0000000000000283","volume":"11","author":"JB Sacha","year":"2016","unstructured":"Sacha JB, Ndhlovu LC (2016) Strategies to target non-T-cell HIV reservoirs. Curr Opin HIV AIDS 11:376\u2013382. https:\/\/doi.org\/10.1097\/COH.0000000000000283","journal-title":"Curr Opin HIV AIDS"},{"key":"3156_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/82_2017_74","volume":"417","author":"G Darcis","year":"2018","unstructured":"Darcis G, Van Driessche B, Bouchat S et al (2018) Molecular control of HIV and SIV latency. Curr Top Microbiol Immunol 417:1\u201322. https:\/\/doi.org\/10.1007\/82_2017_74","journal-title":"Curr Top Microbiol Immunol"},{"key":"3156_CR17","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1016\/j.ejca.2005.08.011","volume":"41","author":"I Sadowski","year":"2005","unstructured":"Sadowski I, Mitchell DA (2005) TFII-I and USF (RBF-2) regulate Ras\/MAPK-responsive HIV-1 transcription in T cells. Eur J Cancer 41:2528\u20132536. https:\/\/doi.org\/10.1016\/j.ejca.2005.08.011","journal-title":"Eur J Cancer"},{"key":"3156_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2174\/157016208785132563","volume":"6","author":"I Sadowski","year":"2008","unstructured":"Sadowski I, Lourenco P, Malcolm T (2008) Factors controlling chromatin organization and nucleosome positioning for establishment and maintenance of HIV latency. Curr HIV Res 6:286\u2013295","journal-title":"Curr HIV Res"},{"key":"3156_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-virology-101416-041646","volume":"4","author":"U Mbonye","year":"2017","unstructured":"Mbonye U, Karn J (2017) The molecular basis for human immunodeficiency virus latency. Annu Rev Virol 4:261\u2013285. https:\/\/doi.org\/10.1146\/annurev-virology-101416-041646","journal-title":"Annu Rev Virol"},{"key":"3156_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00133-17","author":"K Nguyen","year":"2017","unstructured":"Nguyen K, Das B, Dobrowolski C, Karn J (2017) Multiple histone lysine methyltransferases are required for the establishment and maintenance of HIV-1 latency. mBio. https:\/\/doi.org\/10.1128\/mbio.00133-17","journal-title":"mBio"},{"key":"3156_CR21","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1128\/JVI.02842-15","volume":"90","author":"FB Hashemi","year":"2016","unstructured":"Hashemi FB, Barreto K, Bernhard W et al (2016) HIV provirus stably reproduces parental latent and induced transcription phenotypes regardless of the chromosomal integration site. J Virol 90:5302\u20135314. https:\/\/doi.org\/10.1128\/JVI.02842-15","journal-title":"J Virol"},{"key":"3156_CR22","first-page":"229","volume":"90","author":"A-MW Turner","year":"2017","unstructured":"Turner A-MW, Margolis DM (2017) Chromatin regulation and the histone code in HIV latency. Yale J Biol Med 90:229\u2013243","journal-title":"Yale J Biol Med"},{"key":"3156_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13148-018-0441-z","volume":"10","author":"S Khan","year":"2018","unstructured":"Khan S, Iqbal M, Tariq M et al (2018) Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins. Clin Epigenet 10:14. https:\/\/doi.org\/10.1186\/s13148-018-0441-z","journal-title":"Clin Epigenet"},{"key":"3156_CR24","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.2174\/1381612823666170622104355","volume":"23","author":"G Mousseau","year":"2017","unstructured":"Mousseau G, Valente ST (2017) Role of host factors on the regulation of tat-mediated HIV-1 transcription. Curr Pharm Des 23:4079\u20134090. https:\/\/doi.org\/10.2174\/1381612823666170622104355","journal-title":"Curr Pharm Des"},{"key":"3156_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.virol.2015.09.016","volume":"486","author":"P Wang","year":"2015","unstructured":"Wang P, Qu X, Zhou X et al (2015) Two cellular microRNAs, miR-196b and miR-1290, contribute to HIV-1 latency. Virology 486:228\u2013238. https:\/\/doi.org\/10.1016\/j.virol.2015.09.016","journal-title":"Virology"},{"key":"3156_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.virol.2017.03.002","volume":"506","author":"JC Zapata","year":"2017","unstructured":"Zapata JC, Campilongo F, Barclay RA et al (2017) The human immunodeficiency virus 1 ASP RNA promotes viral latency by recruiting the polycomb repressor complex 2 and promoting nucleosome assembly. Virology 506:34\u201344. https:\/\/doi.org\/10.1016\/j.virol.2017.03.002","journal-title":"Virology"},{"key":"3156_CR27","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1101\/gad.267609.115","volume":"29","author":"PK Singh","year":"2015","unstructured":"Singh PK, Plumb MR, Ferris AL et al (2015) LEDGF\/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes. Genes Dev 29:2287\u20132297. https:\/\/doi.org\/10.1101\/gad.267609.115","journal-title":"Genes Dev"},{"key":"3156_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12977-014-0134-4","volume":"12","author":"BA Desimmie","year":"2015","unstructured":"Desimmie BA, Weydert C, Schrijvers R et al (2015) HIV-1 IN\/Pol recruits LEDGF\/p75 into viral particles. Retrovirology 12:16. https:\/\/doi.org\/10.1186\/s12977-014-0134-4","journal-title":"Retrovirology"},{"key":"3156_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.chom.2008.05.016","volume":"4","author":"T Lenasi","year":"2008","unstructured":"Lenasi T, Contreras X, Peterlin BM (2008) Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 4:123\u2013133. https:\/\/doi.org\/10.1016\/j.chom.2008.05.016","journal-title":"Cell Host Microbe"},{"key":"3156_CR30","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1128\/JVI.03478-12","volume":"87","author":"MS Dahabieh","year":"2013","unstructured":"Dahabieh MS, Ooms M, Simon V, Sadowski I (2013) A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 Is latent shortly after infection. J Virol 87:4716\u20134727. https:\/\/doi.org\/10.1128\/JVI.03478-12","journal-title":"J Virol"},{"key":"3156_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1742-4690-11-17","volume":"11","author":"MS Dahabieh","year":"2014","unstructured":"Dahabieh MS, Ooms M, Brumme C et al (2014) Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFkappaB. Retrovirology 11:17. https:\/\/doi.org\/10.1186\/1742-4690-11-17","journal-title":"Retrovirology"},{"key":"3156_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.virol.2013.07.037","volume":"446","author":"V Calvanese","year":"2013","unstructured":"Calvanese V, Chavez L, Laurent T et al (2013) Dual-color HIV reporters trace a population of latently infected cells and enable their purification. Virology 446:283\u2013292. https:\/\/doi.org\/10.1016\/j.virol.2013.07.037","journal-title":"Virology"},{"key":"3156_CR33","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1128\/JVI.02058-08","volume":"83","author":"A Duverger","year":"2009","unstructured":"Duverger A, Jones J, May J et al (2009) Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol 83:3078\u20133093. https:\/\/doi.org\/10.1128\/JVI.02058-08","journal-title":"J Virol"},{"key":"3156_CR34","doi-asserted-by":"publisher","first-page":"e77052","DOI":"10.1371\/journal.pone.0077052.s001","volume":"8","author":"W Bernhard","year":"2013","unstructured":"Bernhard W, Barreto K, Raithatha S, Sadowski I (2013) An Upstream YY1 binding site on the HIV-1 LTR contributes to latent infection. PLoS One 8:e77052. https:\/\/doi.org\/10.1371\/journal.pone.0077052.s001","journal-title":"PLoS One"},{"key":"3156_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02225-17","author":"SD Rezaei","year":"2018","unstructured":"Rezaei SD, Lu HK, Chang JJ et al (2018) The pathway to establishing HIV latency is critical to how latency is maintained and reversed. J Virol. https:\/\/doi.org\/10.1128\/jvi.02225-17","journal-title":"J Virol"},{"key":"3156_CR36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2055-6640(20)30490-8","volume":"1","author":"DA Kulpa","year":"2015","unstructured":"Kulpa DA, Chomont N (2015) HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad 1:59\u201366","journal-title":"J Virus Erad"},{"key":"3156_CR37","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1182\/blood-2013-03-488411","volume":"122","author":"L Westera","year":"2013","unstructured":"Westera L, Drylewicz J, den Braber I et al (2013) Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans. Blood 122:2205\u20132212. https:\/\/doi.org\/10.1182\/blood-2013-03-488411","journal-title":"Blood"},{"key":"3156_CR38","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1084\/jem.187.7.1139","volume":"187","author":"LP Yang","year":"1998","unstructured":"Yang LP, Riley JL, Carroll RG et al (1998) Productive infection of neonatal CD8+ T lymphocytes by HIV-1. J Exp Med 187:1139\u20131144","journal-title":"J Exp Med"},{"key":"3156_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/COH.0000000000000293","volume":"11","author":"JK Wong","year":"2016","unstructured":"Wong JK, Yukl SA (2016) Tissue reservoirs of HIV. Curr Opin HIV AIDS 11:362\u2013370. https:\/\/doi.org\/10.1097\/COH.0000000000000293","journal-title":"Curr Opin HIV AIDS"},{"key":"3156_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/imm.12117","volume":"140","author":"M Collin","year":"2013","unstructured":"Collin M, McGovern N, Haniffa M (2013) Human dendritic cell subsets. Immunology 140:22\u201330. https:\/\/doi.org\/10.1111\/imm.12117","journal-title":"Immunology"},{"key":"3156_CR41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s13365-017-0604-2","volume":"24","author":"GN Llewellyn","year":"2018","unstructured":"Llewellyn GN, Alvarez-Carbonell D, Chateau M et al (2018) HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. J Neurovirol 24:192\u2013203. https:\/\/doi.org\/10.1007\/s13365-017-0604-2","journal-title":"J Neurovirol"},{"key":"3156_CR42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fimmu.2016.00397","volume":"7","author":"C Marban","year":"2016","unstructured":"Marban C, Forouzanfar F, Ait-Ammar A et al (2016) Targeting the brain reservoirs: toward an HIV cure. Front Immunol 7:397. https:\/\/doi.org\/10.3389\/fimmu.2016.00397","journal-title":"Front Immunol"},{"key":"3156_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1128\/jvi.01080-17","volume":"11","author":"MM Painter","year":"2017","unstructured":"Painter MM, Zaikos TD, Collins KL (2017) Quiescence promotes latent HIV infection and resistance to reactivation from latency with histone deacetylase inhibitors. J Virol 11:78. https:\/\/doi.org\/10.1128\/jvi.01080-17","journal-title":"J Virol"},{"key":"3156_CR44","doi-asserted-by":"publisher","first-page":"9026","DOI":"10.1073\/pnas.97.16.9026","volume":"97","author":"DG Myszka","year":"2000","unstructured":"Myszka DG, Sweet RW, Hensley P et al (2000) Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci USA 97:9026\u20139031","journal-title":"Proc Natl Acad Sci USA"},{"key":"3156_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2014.02.015","author":"TD Zaikos","year":"2014","unstructured":"Zaikos TD, Collins KL (2014) Long-lived reservoirs of HIV-1. Trends Microbiol. https:\/\/doi.org\/10.1016\/j.tim.2014.02.015","journal-title":"Trends Microbiol"},{"key":"3156_CR46","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1016\/j.celrep.2018.11.104","volume":"25","author":"TD Zaikos","year":"2018","unstructured":"Zaikos TD, Terry VH, Sebastian Kettinger NT et al (2018) Hematopoietic stem and progenitor cells are a distinct HIV reservoir that contributes to persistent viremia in suppressed patients. Cell Rep 25:3759\u20133773. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.104","journal-title":"Cell Rep"},{"key":"3156_CR47","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/glia.23310","volume":"66","author":"C Barat","year":"2018","unstructured":"Barat C, Proust A, Deshiere A et al (2018) Astrocytes sustain long-term productive HIV-1 infection without establishment of reactivable viral latency. Glia 66:1363\u20131381. https:\/\/doi.org\/10.1002\/glia.23310","journal-title":"Glia"},{"key":"3156_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12223-016-0474-7","volume":"62","author":"Z Melkova","year":"2017","unstructured":"Melkova Z, Shankaran P, Madlenakova M, Bodor J (2017) Current views on HIV-1 latency, persistence, and cure. Folia Microbiol (Praha) 62:73\u201387. https:\/\/doi.org\/10.1007\/s12223-016-0474-7","journal-title":"Folia Microbiol (Praha)"},{"key":"3156_CR49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/bies.201200170","volume":"35","author":"L Shan","year":"2013","unstructured":"Shan L, Siliciano RF (2013) From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays 35:544\u2013552. https:\/\/doi.org\/10.1002\/bies.201200170","journal-title":"Bioessays"},{"key":"3156_CR50","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1038\/s41467-018-06843-5","volume":"9","author":"DB Reeves","year":"2018","unstructured":"Reeves DB, Duke ER, Wagner TA et al (2018) A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nat Commun 9:4811. https:\/\/doi.org\/10.1038\/s41467-018-06843-5","journal-title":"Nat Commun"},{"key":"3156_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/82_2017_77","volume":"417","author":"AL Hill","year":"2018","unstructured":"Hill AL (2018) Mathematical models of HIV latency. Curr Top Microbiol Immunol 417:131\u2013156. https:\/\/doi.org\/10.1007\/82_2017_77","journal-title":"Curr Top Microbiol Immunol"},{"key":"3156_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12977-017-0344-7","volume":"14","author":"M Ara\u00ednga","year":"2017","unstructured":"Ara\u00ednga M, Edagwa B, Mosley RL et al (2017) A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology 14:17. https:\/\/doi.org\/10.1186\/s12977-017-0344-7","journal-title":"Retrovirology"},{"key":"3156_CR53","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.antiviral.2009.09.016","volume":"85","author":"V Dahl","year":"2010","unstructured":"Dahl V, Josefsson L, Palmer S (2010) HIV reservoirs, latency, and reactivation: prospects for eradication. Antivir Res 85:286\u2013294. https:\/\/doi.org\/10.1016\/j.antiviral.2009.09.016","journal-title":"Antivir Res"},{"key":"3156_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.cell.2013.09.044","volume":"155","author":"DS Ruelas","year":"2013","unstructured":"Ruelas DS, Greene WC (2013) An integrated overview of HIV-1 latency. Cell 155:519\u2013529. https:\/\/doi.org\/10.1016\/j.cell.2013.09.044","journal-title":"Cell"},{"key":"3156_CR55","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1093\/infdis\/jix005","volume":"215","author":"EA Boritz","year":"2017","unstructured":"Boritz EA, Douek DC (2017) Perspectives on human immunodeficiency virus (HIV) cure: HIV persistence in tissue. J Infect Dis 215:S128\u2013S133. https:\/\/doi.org\/10.1093\/infdis\/jix005","journal-title":"J Infect Dis"},{"key":"3156_CR56","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11904-019-00428-7","volume":"214","author":"RT Veenhuis","year":"2019","unstructured":"Veenhuis RT, Clements JE, Gama L (2019) HIV eradication strategies: implications for the central nervous system. Curr HIV\/AIDS Rep 214:231\u2013239. https:\/\/doi.org\/10.1007\/s11904-019-00428-7","journal-title":"Curr HIV\/AIDS Rep"},{"key":"3156_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-016-0114-y","author":"G H\u00fctter","year":"2016","unstructured":"H\u00fctter G (2016) Stem cell transplantation in strategies for curing HIV\/AIDS. AIDS Res Ther. https:\/\/doi.org\/10.1186\/s12981-016-0114-y","journal-title":"AIDS Res Ther"},{"key":"3156_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1027-4","author":"RK Gupta","year":"2019","unstructured":"Gupta RK, Abdul-jawad S, McCoy LE et al (2019) HIV-1 remission following CCR1\u039432\/\u039432 haematopoietic stem-cell transplantation. Nature. https:\/\/doi.org\/10.1038\/s41586-019-1027-4","journal-title":"Nature"},{"key":"3156_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.02.021","author":"CP Passaes","year":"2014","unstructured":"Passaes CP, S\u00e1ez-Ciri\u00f3n A (2014) HIV cure research: advances and prospects. Virology. https:\/\/doi.org\/10.1016\/j.virol.2014.02.021","journal-title":"Virology"},{"key":"3156_CR60","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jmb.2014.07.022","volume":"427","author":"M Lusic","year":"2015","unstructured":"Lusic M, Giacca M (2015) Regulation of HIV-1 latency by chromatin structure and nuclear architecture. J Mol Biol 427:688\u2013694. https:\/\/doi.org\/10.1016\/j.jmb.2014.07.022","journal-title":"J Mol Biol"},{"key":"3156_CR61","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12977-016-0325-2","volume":"14","author":"J Symons","year":"2017","unstructured":"Symons J, Chopra A, Malantinkova E et al (2017) HIV integration sites in latently infected cell lines: evidence of ongoing replication. Retrovirology 14:2. https:\/\/doi.org\/10.1186\/s12977-016-0325-2","journal-title":"Retrovirology"},{"key":"3156_CR62","doi-asserted-by":"publisher","first-page":"12112","DOI":"10.7554\/elife.18296","volume":"5","author":"EJ Greenwood","year":"2016","unstructured":"Greenwood EJ, Matheson NJ, Wals K et al (2016) Temporal proteomic analysis of HIV infection reveals remodelling of the host phosphoproteome by lentiviral Vif variants. eLife 5:12112. https:\/\/doi.org\/10.7554\/elife.18296","journal-title":"eLife"},{"key":"3156_CR63","doi-asserted-by":"publisher","first-page":"9148","DOI":"10.1128\/JVI.01297-13","volume":"87","author":"M Iglesias-Ussel","year":"2013","unstructured":"Iglesias-Ussel M, Vandergeeten C, Marchionni L et al (2013) High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. J Virol 87:9148\u20139158. https:\/\/doi.org\/10.1128\/JVI.01297-13","journal-title":"J Virol"},{"key":"3156_CR64","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature21710","volume":"543","author":"B Descours","year":"2017","unstructured":"Descours B, Petitjean G, L\u00f3pez-Zaragoza J-L et al (2017) CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature 543:564\u2013567. https:\/\/doi.org\/10.1038\/nature21710","journal-title":"Nature"},{"key":"3156_CR65","doi-asserted-by":"publisher","first-page":"15541","DOI":"10.1038\/s41598-018-33749-5","volume":"8","author":"M Garc\u00eda","year":"2018","unstructured":"Garc\u00eda M, Navarrete-Mu\u00f1oz MA, Ligos JM et al (2018) CD32 expression is not associated to HIV-DNA content in CD4 cell subsets of individuals with different levels of HIV control. Sci Rep 8:15541. https:\/\/doi.org\/10.1038\/s41598-018-33749-5","journal-title":"Sci Rep"},{"key":"3156_CR66","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/1873-3468.12226","volume":"590","author":"B Lucic","year":"2016","unstructured":"Lucic B, Lusic M (2016) Connecting HIV-1 integration and transcription: a step toward new treatments. FEBS Lett 590:1927\u20131939. https:\/\/doi.org\/10.1002\/1873-3468.12226","journal-title":"FEBS Lett"},{"key":"3156_CR67","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.coviro.2013.06.001","volume":"3","author":"M Sgarbanti","year":"2013","unstructured":"Sgarbanti M, Battistini A (2013) Therapeutics for HIV-1 reactivation from latency. Curr Opin Virol 3:394\u2013401. https:\/\/doi.org\/10.1016\/j.coviro.2013.06.001","journal-title":"Curr Opin Virol"},{"key":"3156_CR68","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12879-017-2683-3","volume":"17","author":"K Thorlund","year":"2017","unstructured":"Thorlund K, Horwitz MS, Fife BT et al (2017) Landscape review of current HIV \u201ckick and kill\u201d cure research\u2014some kicking, not enough killing. BMC Infect Dis 17:595. https:\/\/doi.org\/10.1186\/s12879-017-2683-3","journal-title":"BMC Infect Dis"},{"key":"3156_CR69","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1093\/infdis\/jiw618","volume":"215","author":"DM Margolis","year":"2017","unstructured":"Margolis DM, Archin NM (2017) Proviral latency, persistent human immunodeficiency virus infection, and the development of latency reversing agents. J Infect Dis 215:S111\u2013S118. https:\/\/doi.org\/10.1093\/infdis\/jiw618","journal-title":"J Infect Dis"},{"key":"3156_CR70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","volume":"23","author":"Y Kim","year":"2018","unstructured":"Kim Y, Anderson JL, Lewin SR (2018) Getting the \u201cKill\u201d into \u201cShock and Kill\u201d: strategies to eliminate latent HIV. Cell Host Microbe 23:14\u201326. https:\/\/doi.org\/10.1016\/j.chom.2017.12.004","journal-title":"Cell Host Microbe"},{"key":"3156_CR71","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"key":"3156_CR72","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02092-16","author":"J Petravic","year":"2017","unstructured":"Petravic J, Rasmussen TA, Lewin SR et al (2017) Relationship between measures of HIV reactivation and decline of the latent reservoir under latency-reversing agents. J Virol. https:\/\/doi.org\/10.1128\/jvi.02092-16","journal-title":"J Virol"},{"key":"3156_CR73","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/ni.3152","volume":"16","author":"T-W Chun","year":"2015","unstructured":"Chun T-W, Moir S, Fauci AS (2015) HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol 16:584\u2013589. https:\/\/doi.org\/10.1038\/ni.3152","journal-title":"Nat Immunol"},{"key":"3156_CR74","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.molmed.2017.08.006","volume":"23","author":"M Perreau","year":"2017","unstructured":"Perreau M, Banga R, Pantaleo G (2017) Targeted immune interventions for an HIV-1 cure. Trends Mol Med 23:945\u2013961. https:\/\/doi.org\/10.1016\/j.molmed.2017.08.006","journal-title":"Trends Mol Med"},{"key":"3156_CR75","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1172\/JCI97555","volume":"128","author":"S-H Huang","year":"2018","unstructured":"Huang S-H, Ren Y, Thomas AS et al (2018) Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. J Clin Investig 128:876\u2013889. https:\/\/doi.org\/10.1172\/JCI97555","journal-title":"J Clin Investig"},{"key":"3156_CR76","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0092-8674(02)00864-4","volume":"110","author":"ARW Schr\u00f6der","year":"2002","unstructured":"Schr\u00f6der ARW, Shinn P, Chen H et al (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521\u2013529","journal-title":"Cell"},{"key":"3156_CR77","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11262-007-0109-9","volume":"35","author":"T Malcolm","year":"2007","unstructured":"Malcolm T, Chen J, Chang C, Sadowski I (2007) Induction of chromosomally integrated HIV-1 LTR requires RBF-2 (USF\/TFII-I) and RAS\/MAPK signaling. Virus Genes 35:215\u2013223. https:\/\/doi.org\/10.1007\/s11262-007-0109-9","journal-title":"Virus Genes"},{"key":"3156_CR78","doi-asserted-by":"publisher","first-page":"e1005545","DOI":"10.1371\/journal.ppat.1005545","volume":"12","author":"RB Jones","year":"2016","unstructured":"Jones RB, Mueller S, O\u2019Connor R et al (2016) A subset of latency-reversing agents expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes. PLoS Pathog 12:e1005545. https:\/\/doi.org\/10.1371\/journal.ppat.1005545","journal-title":"PLoS Pathog"},{"key":"3156_CR79","doi-asserted-by":"publisher","first-page":"160","DOI":"10.15252\/emmm.201708193","volume":"10","author":"P Hashemi","year":"2018","unstructured":"Hashemi P, Barreto K, Bernhard W et al (2018) Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency. EMBO Mol Med 10:160\u2013174. https:\/\/doi.org\/10.15252\/emmm.201708193","journal-title":"EMBO Mol Med"},{"key":"3156_CR80","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.imlet.2018.02.004","volume":"196","author":"K Bashiri","year":"2018","unstructured":"Bashiri K, Rezaei N, Nasi M, Cossarizza A (2018) The role of latency reversal agents in the cure of HIV: a review of current data. Immunol Lett 196:135\u2013139. https:\/\/doi.org\/10.1016\/j.imlet.2018.02.004","journal-title":"Immunol Lett"},{"key":"3156_CR81","doi-asserted-by":"publisher","first-page":"e1003834","DOI":"10.1371\/journal.ppat.1003834","volume":"9","author":"CA Spina","year":"2013","unstructured":"Spina CA, Anderson J, Archin NM et al (2013) An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9:e1003834. https:\/\/doi.org\/10.1371\/journal.ppat.1003834","journal-title":"PLoS Pathog"},{"key":"3156_CR82","first-page":"2","volume-title":"Theoretical biology","author":"J Karn","year":"2000","unstructured":"Karn J (2000) Tat, a novel regulator of HIV transcription and latency. In: Kuiken C, McCutchan F, Mellors JW et al (eds) Theoretical biology. Biophysics Group, London, pp 2\u201318"},{"key":"3156_CR83","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.tim.2015.11.003","volume":"24","author":"TA Rasmussen","year":"2016","unstructured":"Rasmussen TA, Tolstrup M, S\u00f8gaard OS (2016) Reversal of latency as part of a cure for HIV-1. Trends Microbiol 24:90\u201397. https:\/\/doi.org\/10.1016\/j.tim.2015.11.003","journal-title":"Trends Microbiol"},{"key":"3156_CR84","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01931-17","author":"N Madrid-Elena","year":"2018","unstructured":"Madrid-Elena N, Garc\u00eda-Bermejo ML, Serrano-Villar S et al (2018) Maraviroc is associated with latent HIV-1 reactivation through NF-\u03baB activation in resting CD4+ T cells from HIV-infected individuals on suppressive antiretroviral therapy. J Virol. https:\/\/doi.org\/10.1128\/jvi.01931-17","journal-title":"J Virol"},{"key":"3156_CR85","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02084-16","author":"MA Rochat","year":"2017","unstructured":"Rochat MA, Schlaepfer E, Speck RF (2017) Promising role of toll-like receptor 8 agonist in concert with prostratin for activation of silent HIV. J Virol. https:\/\/doi.org\/10.1128\/jvi.02084-16","journal-title":"J Virol"},{"key":"3156_CR86","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1172\/JCI92684","volume":"127","author":"NM Archin","year":"2017","unstructured":"Archin NM, Kirchherr JL, Sung JA et al (2017) Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J Clin Investig 127:3126\u20133135. https:\/\/doi.org\/10.1172\/JCI92684","journal-title":"J Clin Investig"},{"key":"3156_CR87","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1016\/j.febslet.2011.10.018","volume":"585","author":"W Bernhard","year":"2011","unstructured":"Bernhard W, Barreto K, Saunders A et al (2011) The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett 585:3549\u20133554. https:\/\/doi.org\/10.1016\/j.febslet.2011.10.018","journal-title":"FEBS Lett"},{"key":"3156_CR88","doi-asserted-by":"publisher","first-page":"9451","DOI":"10.1038\/s41598-017-07157-0","volume":"7","author":"P Wang","year":"2017","unstructured":"Wang P, Lu P, Qu X et al (2017) Reactivation of HIV-1 from latency by an ingenol derivative from Euphorbia kansui. Sci Rep 7:9451. https:\/\/doi.org\/10.1038\/s41598-017-07157-0","journal-title":"Sci Rep"},{"key":"3156_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2016.09.015","volume":"227","author":"H Lim","year":"2017","unstructured":"Lim H, Kim K-C, Son J et al (2017) Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor. Virus Res 227:1\u20135. https:\/\/doi.org\/10.1016\/j.virusres.2016.09.015","journal-title":"Virus Res"},{"key":"3156_CR90","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.mehy.2017.05.032","volume":"104","author":"J Finley","year":"2017","unstructured":"Finley J (2017) Elimination of cancer stem cells and reactivation of latent HIV-1 via AMPK activation: common mechanism of action linking inhibition of tumorigenesis and the potential eradication of HIV-1. Med Hypotheses 104:133\u2013146. https:\/\/doi.org\/10.1016\/j.mehy.2017.05.032","journal-title":"Med Hypotheses"},{"key":"3156_CR91","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev-med-052716-031710","volume":"69","author":"AM Spivak","year":"2018","unstructured":"Spivak AM, Planelles V (2018) Novel latency reversal agents for HIV-1 cure. Annu Rev Med 69:421\u2013436. https:\/\/doi.org\/10.1146\/annurev-med-052716-031710","journal-title":"Annu Rev Med"},{"key":"3156_CR92","doi-asserted-by":"publisher","first-page":"e0211746","DOI":"10.1371\/journal.pone.0211746","volume":"14","author":"M Bobardt","year":"2019","unstructured":"Bobardt M, Kuo J, Chatterji U et al (2019) The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate. PLoS One 14:e0211746. https:\/\/doi.org\/10.1371\/journal.pone.0211746","journal-title":"PLoS One"},{"key":"3156_CR93","doi-asserted-by":"publisher","first-page":"e02056-17","DOI":"10.1128\/JVI.02056-17","volume":"92","author":"E Abner","year":"2018","unstructured":"Abner E, Stoszko M, Zeng L et al (2018) A new quinoline BRD4 inhibitor targets a distinct latent HIV-1 reservoir for reactivation from other \u201cShock\u201d drugs. J Virol 92:e02056-17. https:\/\/doi.org\/10.1128\/JVI.02056-17","journal-title":"J Virol"},{"key":"3156_CR94","doi-asserted-by":"publisher","first-page":"10657","DOI":"10.1038\/s41598-017-10728-w","volume":"7","author":"J Wu","year":"2017","unstructured":"Wu J, Ao M-T, Shao R et al (2017) A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter. Sci Rep 7:10657. https:\/\/doi.org\/10.1038\/s41598-017-10728-w","journal-title":"Sci Rep"},{"key":"3156_CR95","doi-asserted-by":"publisher","first-page":"e944","DOI":"10.1038\/cddis.2013.473","volume":"4","author":"B Chirullo","year":"2013","unstructured":"Chirullo B, Sgarbanti R, Limongi D et al (2013) A candidate anti-HIV reservoir compound, auranofin, exerts a selective \u201canti-memory\u201d effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis 4:e944. https:\/\/doi.org\/10.1038\/cddis.2013.473","journal-title":"Cell Death Dis"},{"key":"3156_CR96","doi-asserted-by":"publisher","first-page":"e84964","DOI":"10.1371\/journal.pone.0084964.t003","volume":"9","author":"G Doyon","year":"2014","unstructured":"Doyon G, Sobolewski MD, Huber K et al (2014) Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110\u03b1 that reactivates latent HIV-1. PLoS One 9:e84964. https:\/\/doi.org\/10.1371\/journal.pone.0084964.t003","journal-title":"PLoS One"},{"key":"3156_CR97","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1097\/QAD.0000000000001649","volume":"31","author":"C Duquenne","year":"2017","unstructured":"Duquenne C, Gimenez S, Guigues A et al (2017) Reversing HIV latency via sphingosine-1-phosphate receptor 1 signaling. AIDS 31:2443\u20132454. https:\/\/doi.org\/10.1097\/QAD.0000000000001649","journal-title":"AIDS"},{"key":"3156_CR98","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3797\/scipharm.1502-01","volume":"83","author":"KA Smith","year":"2015","unstructured":"Smith KA, Lin X, Bolshakov O et al (2015) Activation of HIV-1 with nanoparticle-packaged small-molecule protein phosphatase-1-targeting compound. Sci Pharm 83:535\u2013548. https:\/\/doi.org\/10.3797\/scipharm.1502-01","journal-title":"Sci Pharm"},{"key":"3156_CR99","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12977-015-0190-4","volume":"12","author":"M Tyagi","year":"2015","unstructured":"Tyagi M, Iordanskiy S, Ammosova T et al (2015) Reactivation of latent HIV-1 provirus via targeting protein phosphatase-1. Retrovirology 12:63. https:\/\/doi.org\/10.1186\/s12977-015-0190-4","journal-title":"Retrovirology"},{"key":"3156_CR100","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.chom.2015.08.009","volume":"18","author":"L Pache","year":"2015","unstructured":"Pache L, Dutra MS, Spivak AM et al (2015) BIRC2\/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by smac mimetics to promote reversal of viral latency. Cell Host Microbe 18:345\u2013353. https:\/\/doi.org\/10.1016\/j.chom.2015.08.009","journal-title":"Cell Host Microbe"},{"key":"3156_CR101","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/9498","volume":"5","author":"TW Chun","year":"1999","unstructured":"Chun TW, Engel D, Mizell SB et al (1999) Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 5:651\u2013655. https:\/\/doi.org\/10.1038\/9498","journal-title":"Nat Med"},{"key":"3156_CR102","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1172\/jci.insight.122673","volume":"3","author":"AB Macedo","year":"2018","unstructured":"Macedo AB, Novis CL, De Assis CM et al (2018) Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI Insight 3:20. https:\/\/doi.org\/10.1172\/jci.insight.122673","journal-title":"JCI Insight"},{"key":"3156_CR103","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02166-16","author":"A Tsai","year":"2017","unstructured":"Tsai A, Irrinki A, Kaur J et al (2017) Toll-like receptor 7 agonist GS-9620 induces HIV expression and HIV-specific immunity in cells from HIV-infected individuals on suppressive antiretroviral therapy. J Virol. https:\/\/doi.org\/10.1128\/jvi.02166-16","journal-title":"J Virol"},{"key":"3156_CR104","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/COH.0000000000000279","volume":"11","author":"TA Rasmussen","year":"2016","unstructured":"Rasmussen TA, Lewin SR (2016) Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents? Curr Opin HIV AIDS 11:394\u2013401. https:\/\/doi.org\/10.1097\/COH.0000000000000279","journal-title":"Curr Opin HIV AIDS"},{"key":"3156_CR105","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1172\/JCI80566","volume":"126","author":"RB Jones","year":"2016","unstructured":"Jones RB, Walker BD (2016) HIV-specific CD8+ T cells and HIV eradication. J Clin Investig 126:455\u2013463. https:\/\/doi.org\/10.1172\/JCI80566","journal-title":"J Clin Investig"},{"key":"3156_CR106","doi-asserted-by":"publisher","first-page":"e1006575","DOI":"10.1371\/journal.ppat.1006575","volume":"13","author":"MD Marsden","year":"2017","unstructured":"Marsden MD, Loy BA, Wu X et al (2017) In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell \u201ckick\u201d and \u201ckill\u201d in strategy for virus eradication. PLoS Pathog 13:e1006575. https:\/\/doi.org\/10.1371\/journal.ppat.1006575","journal-title":"PLoS Pathog"},{"key":"3156_CR107","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41580-018-0010-5","volume":"19","author":"FX Chen","year":"2018","unstructured":"Chen FX, Smith ER, Shilatifard A (2018) Born to run: control of transcription elongation by RNA polymerase II. Nat Publ Gr 19:464\u2013478. https:\/\/doi.org\/10.1038\/s41580-018-0010-5","journal-title":"Nat Publ Gr"},{"key":"3156_CR108","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11481-011-9267-6","volume":"6","author":"N He","year":"2011","unstructured":"He N, Zhou Q (2011) New insights into the control of HIV-1 transcription: when tat meets the 7SK snRNP and super elongation complex (SEC). J Neuroimmune Pharmacol 6:260\u2013268. https:\/\/doi.org\/10.1007\/s11481-011-9267-6","journal-title":"J Neuroimmune Pharmacol"},{"key":"3156_CR109","doi-asserted-by":"publisher","first-page":"e1003338","DOI":"10.1371\/journal.ppat.1003338.s011","volume":"9","author":"UR Mbonye","year":"2013","unstructured":"Mbonye UR, Gokulrangan G, Datt M et al (2013) Phosphorylation of CDK9 at Ser175 enhances HIV transcription and is a marker of activated P-TEFb in CD4\u2009+\u2009T lymphocytes. PLoS Pathog 9:e1003338. https:\/\/doi.org\/10.1371\/journal.ppat.1003338.s011","journal-title":"PLoS Pathog"},{"key":"3156_CR110","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.00994-15","author":"Z Li","year":"2016","unstructured":"Li Z, Lu H, Zhou Q (2016) A minor subset of super elongation complexes plays a predominant role in reversing HIV-1 latency. Mol Cell Biol. https:\/\/doi.org\/10.1128\/mcb.00994-15","journal-title":"Mol Cell Biol"},{"key":"3156_CR111","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/nar\/gks976","volume":"41","author":"Z Li","year":"2013","unstructured":"Li Z, Guo J, Wu Y, Zhou Q (2013) The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res 41:277\u2013287. https:\/\/doi.org\/10.1093\/nar\/gks976","journal-title":"Nucleic Acids Res"},{"key":"3156_CR112","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3389\/fmicb.2017.01035","volume":"8","author":"H Huang","year":"2017","unstructured":"Huang H, Liu S, Jean M et al (2017) A novel bromodomain inhibitor reverses HIV-1 latency through specific binding with BRD4 to promote tat and P-TEFb association. Front Microbiol 8:1035. https:\/\/doi.org\/10.3389\/fmicb.2017.01035","journal-title":"Front Microbiol"},{"key":"3156_CR113","doi-asserted-by":"publisher","first-page":"16646","DOI":"10.1038\/s41598-017-16816-1","volume":"7","author":"P Lu","year":"2017","unstructured":"Lu P, Shen Y, Yang H et al (2017) BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency. Sci Rep 7:16646. https:\/\/doi.org\/10.1038\/s41598-017-16816-1","journal-title":"Sci Rep"},{"key":"3156_CR114","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41594-018-0102-0","volume":"25","author":"H Rahnamoun","year":"2018","unstructured":"Rahnamoun H, Lee J, Sun Z et al (2018) RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation. Nat Struct Mol Biol 25:687\u2013697. https:\/\/doi.org\/10.1038\/s41594-018-0102-0","journal-title":"Nat Struct Mol Biol"},{"key":"3156_CR115","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1128\/JVI.02033-10","volume":"85","author":"S Xing","year":"2011","unstructured":"Xing S, Bullen CK, Shroff NS et al (2011) Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 85:6060\u20136064. https:\/\/doi.org\/10.1128\/JVI.02033-10","journal-title":"J Virol"},{"key":"3156_CR116","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/bs.ircmb.2016.09.004","volume":"330","author":"S Fulda","year":"2017","unstructured":"Fulda S (2017) Smac mimetics to therapeutically target IAP proteins in cancer. Int Rev Cell Mol Biol 330:157\u2013169. https:\/\/doi.org\/10.1016\/bs.ircmb.2016.09.004","journal-title":"Int Rev Cell Mol Biol"},{"key":"3156_CR117","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nsmb.3328","volume":"24","author":"H-C Chen","year":"2017","unstructured":"Chen H-C, Martinez JP, Zorita E et al (2017) Position effects influence HIV latency reversal. Nat Struct Mol Biol 24:47\u201354. https:\/\/doi.org\/10.1038\/nsmb.3328","journal-title":"Nat Struct Mol Biol"},{"key":"3156_CR118","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1172\/JCI80142","volume":"125","author":"GM Laird","year":"2015","unstructured":"Laird GM, Bullen CK, Rosenbloom DIS et al (2015) Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Investig 125:1901\u20131912. https:\/\/doi.org\/10.1172\/JCI80142","journal-title":"J Clin Investig"},{"key":"3156_CR119","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1172\/jci.insight.95676","volume":"3","author":"X Tang","year":"2018","unstructured":"Tang X, Lu H, Dooner M et al (2018) Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes. JCI Insight 3:318. https:\/\/doi.org\/10.1172\/jci.insight.95676","journal-title":"JCI Insight"},{"key":"3156_CR120","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/mt.2016.117","volume":"24","author":"G Geng","year":"2016","unstructured":"Geng G, Liu B, Chen C et al (2016) Development of an attenuated tat protein as a highly-effective agent to specifically activate HIV-1 latency. Mol Ther 24:1528\u20131537. https:\/\/doi.org\/10.1038\/mt.2016.117","journal-title":"Mol Ther"},{"key":"3156_CR121","doi-asserted-by":"publisher","first-page":"e0158294","DOI":"10.1371\/journal.pone.0158294","volume":"11","author":"JK Bialek","year":"2016","unstructured":"Bialek JK, Dunay GA, Voges M et al (2016) Targeted HIV-1 latency reversal using CRISPR\/Cas9-derived transcriptional activator systems. PLoS One 11:e0158294. https:\/\/doi.org\/10.1371\/journal.pone.0158294","journal-title":"PLoS One"},{"key":"3156_CR122","doi-asserted-by":"publisher","first-page":"e0150037","DOI":"10.1371\/journal.pone.0150037","volume":"11","author":"P Perdig\u00e3o","year":"2016","unstructured":"Perdig\u00e3o P, Gaj T, Santa-Marta M et al (2016) Reactivation of latent HIV-1 expression by engineered TALE transcription factors. PLoS One 11:e0150037. https:\/\/doi.org\/10.1371\/journal.pone.0150037","journal-title":"PLoS One"},{"key":"3156_CR123","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/335563a0","volume":"335","author":"I Sadowski","year":"1988","unstructured":"Sadowski I, Ma J, Triezenberg S, Ptashne M (1988) GAL4-VP16 is an unusually potent transcriptional activator. Nature 335:563\u2013564. https:\/\/doi.org\/10.1038\/335563a0","journal-title":"Nature"},{"key":"3156_CR124","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1128\/MCB.21.14.4568-4578.2001","volume":"21","author":"GA Stafford","year":"2001","unstructured":"Stafford GA, Morse RH (2001) GCN5 dependence of chromatin remodeling and transcriptional activation by the GAL4 and VP16 activation domains in budding yeast. Mol Cell Biol 21:4568\u20134578. https:\/\/doi.org\/10.1128\/MCB.21.14.4568-4578.2001","journal-title":"Mol Cell Biol"},{"key":"3156_CR125","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.biocel.2008.07.016","volume":"41","author":"H Zhang","year":"2009","unstructured":"Zhang H (2009) Reversal of HIV-1 latency with anti-microRNA inhibitors. Int J Biochem Cell Biol 41:451\u2013454. https:\/\/doi.org\/10.1016\/j.biocel.2008.07.016","journal-title":"Int J Biochem Cell Biol"},{"key":"3156_CR126","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1099\/jgv.0.000402","volume":"97","author":"U Timilsina","year":"2016","unstructured":"Timilsina U, Gaur R (2016) Modulation of apoptosis and viral latency\u2014an axis to be well understood for successful cure of human immunodeficiency virus. J Gen Virol 97:813\u2013824. https:\/\/doi.org\/10.1099\/jgv.0.000402","journal-title":"J Gen Virol"},{"key":"3156_CR127","doi-asserted-by":"publisher","first-page":"8957","DOI":"10.1038\/s41598-017-09129-w","volume":"7","author":"H Tateishi","year":"2017","unstructured":"Tateishi H, Monde K, Anraku K et al (2017) A clue to unprecedented strategy to HIV eradication: \u201cLock-in and apoptosis\u201d. Sci Rep 7:8957. https:\/\/doi.org\/10.1038\/s41598-017-09129-w","journal-title":"Sci Rep"},{"key":"3156_CR128","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00012-17","author":"NW Cummins","year":"2017","unstructured":"Cummins NW, Sainski-Nguyen AM, Natesampillai S et al (2017) Maintenance of the HIV reservoir is antagonized by selective BCL2 inhibition. J Virol. https:\/\/doi.org\/10.1128\/jvi.00012-17","journal-title":"J Virol"},{"key":"3156_CR129","doi-asserted-by":"publisher","first-page":"16179","DOI":"10.1038\/s41598-017-15532-0","volume":"7","author":"LE Fong","year":"2017","unstructured":"Fong LE, Sulistijo ES, Miller-Jensen K (2017) Systems analysis of latent HIV reversal reveals altered stress kinase signaling and increased cell death in infected T cells. Sci Rep 7:16179. https:\/\/doi.org\/10.1038\/s41598-017-15532-0","journal-title":"Sci Rep"},{"key":"3156_CR130","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1074\/jbc.RA118.005798","volume":"294","author":"K Matsuda","year":"2019","unstructured":"Matsuda K, Kobayakawa T, Tsuchiya K et al (2019) Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal. J Biol Chem 294:116\u2013129. https:\/\/doi.org\/10.1074\/jbc.RA118.005798","journal-title":"J Biol Chem"},{"key":"3156_CR131","doi-asserted-by":"publisher","first-page":"e0151572","DOI":"10.1371\/journal.pone.0151572","volume":"11","author":"J Wen","year":"2016","unstructured":"Wen J, Yan M, Liu Y et al (2016) Specific elimination of latently HIV-1 infected cells using HIV-1 protease-sensitive toxin nanocapsules. PLoS One 11:e0151572. https:\/\/doi.org\/10.1371\/journal.pone.0151572","journal-title":"PLoS One"},{"key":"3156_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.12.003","author":"G Darcis","year":"2017","unstructured":"Darcis G, Van Driessche B, van Lint C (2017) HIV latency: should we shock or lock? Trends Immunol. https:\/\/doi.org\/10.1016\/j.it.2016.12.003","journal-title":"Trends Immunol"},{"key":"3156_CR133","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12981-017-0157-8","volume":"14","author":"A Kwarteng","year":"2017","unstructured":"Kwarteng A, Ahuno ST, Kwakye-Nuako G (2017) The therapeutic landscape of HIV-1 via genome editing. AIDS Res Ther 14:32. https:\/\/doi.org\/10.1186\/s12981-017-0157-8","journal-title":"AIDS Res Ther"},{"key":"3156_CR134","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.etap.2014.01.023","volume":"37","author":"CR Wang","year":"2014","unstructured":"Wang CR, Zhou R, Ng TB et al (2014) First report on isolation of methyl gallate with antioxidant, anti-HIV-1 and HIV-1 enzyme inhibitory activities from a mushroom (Pholiota adiposa). Environ Toxicol Pharmacol 37:626\u2013637. https:\/\/doi.org\/10.1016\/j.etap.2014.01.023","journal-title":"Environ Toxicol Pharmacol"},{"key":"3156_CR135","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1128\/JVI.69.10.6577-6580.1995","volume":"69","author":"G Pengue","year":"1995","unstructured":"Pengue G, Caputo A, Rossi C et al (1995) Transcriptional silencing of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by the Kr\u00fcppel-associated box repressor domain targeted to the transactivating response element. J Virol 69:6577\u20136580","journal-title":"J Virol"},{"key":"3156_CR136","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.virusres.2017.07.020","volume":"244","author":"G Wang","year":"2018","unstructured":"Wang G, Zhao N, Berkhout B, Das AT (2018) CRISPR-Cas based antiviral strategies against HIV-1. Virus Res 244:321\u2013332. https:\/\/doi.org\/10.1016\/j.virusres.2017.07.020","journal-title":"Virus Res"},{"key":"3156_CR137","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1128\/mbio.00518-16","volume":"7","author":"H Jin","year":"2016","unstructured":"Jin H, Li D, Sivakumaran H et al (2016) Shutdown of HIV-1 transcription in T cells by nullbasic, a mutant tat protein. mBio 7:67. https:\/\/doi.org\/10.1128\/mbio.00518-16","journal-title":"mBio"},{"key":"3156_CR138","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jmb.2003.12.028","volume":"336","author":"AIH Murchie","year":"2004","unstructured":"Murchie AIH, Davis B, Isel C et al (2004) Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA. J Mol Biol 336:625\u2013638. https:\/\/doi.org\/10.1016\/j.jmb.2003.12.028","journal-title":"J Mol Biol"},{"key":"3156_CR139","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ymthe.2005.07.524","volume":"12","author":"M-J Li","year":"2005","unstructured":"Li M-J, Kim J, Li S et al (2005) Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR140 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 12:900\u2013909. https:\/\/doi.org\/10.1016\/j.ymthe.2005.07.524","journal-title":"Mol Ther"},{"key":"3156_CR140","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1038\/mtna.2015.31","volume":"4","author":"C Ahlenstiel","year":"2015","unstructured":"Ahlenstiel C, Mendez C, Lim STH et al (2015) Novel RNA duplex locks HIV-1 in a latent state via chromatin-mediated transcriptional silencing. Mol Ther Nucleic Acids 4:e261. https:\/\/doi.org\/10.1038\/mtna.2015.31","journal-title":"Mol Ther Nucleic Acids"},{"key":"3156_CR141","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/AID.2011.0017","volume":"27","author":"DM Margolis","year":"2011","unstructured":"Margolis DM (2011) Eradication therapies for HIV infection: time to begin again. AIDS Res Hum Retrovir 27:347\u2013353. https:\/\/doi.org\/10.1089\/AID.2011.0017","journal-title":"AIDS Res Hum Retrovir"},{"key":"3156_CR142","doi-asserted-by":"publisher","first-page":"7771","DOI":"10.1093\/nar\/gkt571","volume":"41","author":"X Qu","year":"2013","unstructured":"Qu X, Wang P, Ding D et al (2013) Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res 41:7771\u20137782. https:\/\/doi.org\/10.1093\/nar\/gkt571","journal-title":"Nucleic Acids Res"},{"key":"3156_CR143","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.virusres.2018.04.002","volume":"250","author":"Q Wang","year":"2018","unstructured":"Wang Q, Liu S, Liu Z et al (2018) Genome scale screening identification of SaCas9\/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection. Virus Res 250:21\u201330. https:\/\/doi.org\/10.1016\/j.virusres.2018.04.002","journal-title":"Virus Res"},{"key":"3156_CR144","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.ymthe.2017.03.012","volume":"25","author":"C Yin","year":"2017","unstructured":"Yin C, Zhang T, Qu X et al (2017) In\u00a0vivo excision of HIV-1 provirus by saCas9 and multiplex single-guide RNAs in animal models. Mol Ther 25:1168\u20131186. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.012","journal-title":"Mol Ther"},{"key":"3156_CR145","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.3389\/fmicb.2018.02940","volume":"9","author":"AG Allen","year":"2018","unstructured":"Allen AG, Chung C-H, Atkins A et al (2018) Gene editing of HIV-1 Co-receptors to prevent and\/or cure virus infection. Front Microbiol 9:2940. https:\/\/doi.org\/10.3389\/fmicb.2018.02940","journal-title":"Front Microbiol"},{"key":"3156_CR146","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/COH.0000000000000284","volume":"11","author":"C Spragg","year":"2016","unstructured":"Spragg C, De Silva Feelixge H, Jerome KR (2016) Cell and gene therapy strategies to eradicate HIV reservoirs. Curr Opin HIV AIDS 11:442\u2013449. https:\/\/doi.org\/10.1097\/COH.0000000000000284","journal-title":"Curr Opin HIV AIDS"},{"key":"3156_CR147","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1093\/infdis\/jiw555","volume":"215","author":"G Ferrari","year":"2017","unstructured":"Ferrari G, Pollara J, Tomaras GD, Haynes BF (2017) Humoral and innate antiviral immunity as tools to clear persistent HIV infection. J Infect Dis 215:S152\u2013S159. https:\/\/doi.org\/10.1093\/infdis\/jiw555","journal-title":"J Infect Dis"},{"key":"3156_CR148","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12981-017-0177-4","volume":"14","author":"J Pankrac","year":"2017","unstructured":"Pankrac J, Klein K, Mann JFS (2017) Eradication of HIV-1 latent reservoirs through therapeutic vaccination. AIDS Res Ther 14:45. https:\/\/doi.org\/10.1186\/s12981-017-0177-4","journal-title":"AIDS Res Ther"},{"key":"3156_CR149","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00235-18","author":"C Garrido","year":"2018","unstructured":"Garrido C, Abad-Fernandez M, Tuyishime M et al (2018) Interleukin-15-stimulated natural killer cells clear HIV-1-infected cells following latency reversal ex vivo. J Virol. https:\/\/doi.org\/10.1128\/jvi.00235-18","journal-title":"J Virol"},{"key":"3156_CR150","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ni.3647","volume":"18","author":"SI Gringhuis","year":"2017","unstructured":"Gringhuis SI, Hertoghs N, Kaptein TM et al (2017) HIV-1 blocks the signaling adaptor MAVS to evade antiviral host defense after sensing of abortive HIV-1 RNA by the host helicase DDX3. Nat Immunol 18:225\u2013235. https:\/\/doi.org\/10.1038\/ni.3647","journal-title":"Nat Immunol"},{"key":"3156_CR151","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jinf.2017.09.004","volume":"75","author":"G Tapia","year":"2017","unstructured":"Tapia G, H\u00f8jen JF, \u00d6kvist M et al (2017) Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs. J Infect 75:555\u2013571. https:\/\/doi.org\/10.1016\/j.jinf.2017.09.004","journal-title":"J Infect"},{"key":"3156_CR152","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1128\/JVI.02717-15","volume":"90","author":"WS Lee","year":"2016","unstructured":"Lee WS, Richard J, Lichtfuss M et al (2016) Antibody-dependent cellular cytotoxicity against reactivated HIV-1-infected cells. J Virol 90:2021\u20132030. https:\/\/doi.org\/10.1128\/JVI.02717-15","journal-title":"J Virol"},{"key":"3156_CR153","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.it.2017.12.006","volume":"39","author":"MS Parsons","year":"2018","unstructured":"Parsons MS, Cromer D, Davenport MP, Kent SJ (2018) HIV reactivation after partial protection by neutralizing antibodies. Trends Immunol 39:359\u2013366. https:\/\/doi.org\/10.1016\/j.it.2017.12.006","journal-title":"Trends Immunol"},{"key":"3156_CR154","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","volume":"50","author":"JM Martinez-Navio","year":"2019","unstructured":"Martinez-Navio JM, Fuchs SP, Pantry SN et al (2019) Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. IMMUNI 50:567\u2013575. https:\/\/doi.org\/10.1016\/j.immuni.2019.02.005","journal-title":"IMMUNI"},{"key":"3156_CR155","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1742-4690-10-136","volume":"10","author":"H Zhang","year":"2013","unstructured":"Zhang H, Curreli F, Waheed AA et al (2013) Dual-acting stapled peptides target both HIV-1 entry and assembly. Retrovirology 10:136. https:\/\/doi.org\/10.1186\/1742-4690-10-136","journal-title":"Retrovirology"},{"key":"3156_CR156","doi-asserted-by":"publisher","first-page":"e1003993","DOI":"10.1371\/journal.ppat.1003993","volume":"10","author":"NL Bowers","year":"2014","unstructured":"Bowers NL, Helton ES, Huijbregts RPH et al (2014) Immune suppression by neutrophils in HIV-1 infection: role of PD-L1\/PD-1 pathway. PLoS Pathog 10:e1003993. https:\/\/doi.org\/10.1371\/journal.ppat.1003993","journal-title":"PLoS Pathog"},{"key":"3156_CR157","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11904-011-0106-4","volume":"9","author":"F Porichis","year":"2012","unstructured":"Porichis F, Kaufmann DE (2012) Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV AIDS Rep 9:81\u201390. https:\/\/doi.org\/10.1007\/s11904-011-0106-4","journal-title":"Curr HIV AIDS Rep"},{"key":"3156_CR158","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1073\/pnas.122696599","volume":"99","author":"LR Miranda","year":"2002","unstructured":"Miranda LR, Schaefer BC, Kupfer A et al (2002) Cell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules. Proc Natl Acad Sci 99:8031\u20138036. https:\/\/doi.org\/10.1073\/pnas.122696599","journal-title":"Proc Natl Acad Sci"},{"key":"3156_CR159","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3389\/fimmu.2018.02861","volume":"9","author":"H Yang","year":"2018","unstructured":"Yang H, Wallace Z, Dorrell L (2018) Therapeutic targeting of HIV reservoirs: how to give T cells a new direction. Front Immunol 9:2861. https:\/\/doi.org\/10.3389\/fimmu.2018.02861","journal-title":"Front Immunol"},{"key":"3156_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/ph11020032","author":"N Dan","year":"2018","unstructured":"Dan N, Setua S, Kashyap VK et al (2018) Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph11020032","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl 1","key":"3156_CR161","first-page":"199S","volume":"46","author":"DA Mulford","year":"2005","unstructured":"Mulford DA, Scheinberg DA, Jurcic JG (2005) The promise of targeted {alpha}-particle therapy. J Nucl Med 46(Suppl 1):199S\u2013204S","journal-title":"J Nucl Med"},{"key":"3156_CR162","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","volume":"9","author":"K Watanabe","year":"2018","unstructured":"Watanabe K, Kuramitsu S, Posey AD, June CH (2018) Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front Immunol 9:2486. https:\/\/doi.org\/10.3389\/fimmu.2018.02486","journal-title":"Front Immunol"},{"key":"3156_CR163","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/mt.2016.114","volume":"24","author":"H Yang","year":"2016","unstructured":"Yang H, Buisson S, Bossi G et al (2016) Elimination of latently HIV-infected cells from antiretroviral therapy-suppressed subjects by engineered immune-mobilizing T-cell receptors. Mol Ther 24:1913\u20131925. https:\/\/doi.org\/10.1038\/mt.2016.114","journal-title":"Mol Ther"},{"key":"3156_CR164","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1080\/21505594.2017.1371898","volume":"8","author":"T van Montfort","year":"2017","unstructured":"van Montfort T, Speijer D, Berkhout B (2017) Dendritic cells as natural latency reversing agent: a wake-up call for HIV-1. Virulence 8:1494\u20131497. https:\/\/doi.org\/10.1080\/21505594.2017.1371898","journal-title":"Virulence"},{"key":"3156_CR165","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","volume":"18","author":"CR Maldini","year":"2018","unstructured":"Maldini CR, Ellis GI, Riley JL (2018) CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol 18:605\u2013616. https:\/\/doi.org\/10.1038\/s41577-018-0042-2","journal-title":"Nat Rev Immunol"},{"key":"3156_CR166","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12977-018-0396-3","volume":"15","author":"MR Pinzone","year":"2018","unstructured":"Pinzone MR, O\u2019Doherty U (2018) Measuring integrated HIV DNA ex vivo and in vitro provides insights about how reservoirs are formed and maintained. Retrovirology 15:22. https:\/\/doi.org\/10.1186\/s12977-018-0396-3","journal-title":"Retrovirology"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-019-03156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-019-03156-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-019-03156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T13:40:47Z","timestamp":1608039647000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-019-03156-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,25]]},"references-count":166,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3156"],"URL":"https:\/\/doi.org\/10.1007\/s00018-019-03156-8","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,25]]},"assertion":[{"value":"20 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}